The authors reply
- PMID: 35984067
- DOI: 10.1097/CCM.0000000000005597
The authors reply
Conflict of interest statement
Drs. Stockmann and Enghard disclosed that they are currently participating in an industry sponsored multicenter study investigating CytoSorb in septic shock. Dr. Enghard received honoraria from GSK and AstraZeneca, and filed two patents for novel urinary biomarkers outside the submitted work. Dr. Lehner has disclosed that he does not have any potential conflicts of interest.
Comment on
-
Too Bad to Be True: What Can We Reasonably Expect for Treatments of Multiple Organ Failure?Crit Care Med. 2022 Sep 1;50(9):e728-e729. doi: 10.1097/CCM.0000000000005578. Epub 2022 Aug 15. Crit Care Med. 2022. PMID: 35984066 No abstract available.
References
-
- Pappalardo F, Sanfilippo F, Murabito P, et al.:Too Bad to Be True: What Can We Reasonably Expect for Treatments of Multiple Organ Failure? Crit Care Med 2022; 50:e728–e729
-
- Stockmann H, Thelen P, Stroben F, et al.:CytoSorb rescue for COVID-19 patients with vasoplegic shock and multiple organ failure: A prospective, open-label, randomized controlled pilot study. Crit Care Med 2022; 50:964–976
-
- Supady A, Weber E, Rieder M, et al.:Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): A single centre, open-label, randomised, controlled trial. Lancet Respir Med 2021; 9:755–762
-
- Karagiannidis C, Mostert C, Hentschker C, et al.:Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: An observational study. Lancet Respir Med 2020; 8:853–862
-
- Thakkar J, Chand S, Aboodi MS, et al.:Characteristics, outcomes and 60-day hospital mortality of ICU patients with COVID-19 and acute kidney injury. Kidney360 2020; 1:1339–1344
Publication types
LinkOut - more resources
Full Text Sources
